Video Interview: Armed With Promising Clinical Data, Abivax Seeks Partners

Abivax, a French clinical stage antiviral company, is using some of the €58m it raised in its June 2015 IPO to finance the late development of a promising anti-HIV compound and a potential therapeutic vaccine against chronic hepatitis B. CEO Dr. Hartmut Ehrlich reveals to Mike Ward, Informa Pharrna Insights global director of content, how Abivax is working to create a functional cure for HIV patients with a compound AB464 that modulates RNA splicing by inhibiting the activity of the RAF viral protein.

Read the article here 

Press contacts

Caroline Carmagnol 

abivax@alizerp.com

+ 33 6 64 18 99 59 or
+ 33 1 44 54 36 65

 Standard: +33 1 53 83 08 41

More articles in French

Click here